Skip to main content

Table 2 Descriptive statistics of primary outcomes for patients with an endline interview (N = 232)a

From: Pharmacy-based hypertension care employing mHealth in Lagos, Nigeria – a mixed methods feasibility study

 

N

Pharmacy 1

N

Pharmacy 2

N

Pharmacy 3

N

Pharmacy 4

N

Pharmacy 5

N

ALL

n/ median/ mean

%/ IQR/ SD

n/ median/ mean

%/ IQR/ SD

n/ median/ mean

%/ IQR/ SD

n/ median/ mean

%/ IQR/ SD

n/ median/ mean

%/ IQR/ SD

n/ median/ mean

%/ IQR/ SD

Patients with endline interviewa

 

51

  

42

  

32

  

83

  

24

  

232

 

Retention in care

 Activity in mHealth data after enrollment, n (%)

51

41

(80.4)

42

35

(83.3)

32

13

(40.6)

83

67

(80.7)

24

9

(37.5)

232

165

(71.1)

 If active: Duration of activity in mHealth data in months, median (IQR)

41

3.9

(1–5.4)

35

4.2

(2–5.8)

13

3.2

(2–5)

67

3.2

(2.3–5.4)

9

2.7

(0.3–4.6)

165

3.3

(2.2–5.4)

 If active: No. of pharmacy visits in mHealth data, median (IQR)

41

3

(2–6)

35

5

(3–9)

13

4

(2–4)

67

6

(5–7)

9

2

(2–2)

165

5

(3–6)

 If active: No. of self-reported pharmacy visits, median (IQR)b

40

6

(4–7)

34

7

(5–13)

13

10

(7–13)

65

7

(5–13)

9

3

(2–4)

161

6

(4–11)

 If active: Ratio pharmacy visits mHealth data vs. self-reported, median (IQR)

40

1.5

(1.1–2.5)

34

1.4

(1–2)

13

3.3

(2.5–4.3)

65

1.3

(0.8–1.8)

9

1.3

(1–1.5)

161

1.5

(1–2.2)

 If not active: Any self-reported pharmacy visits, n (%)

8

7

(87.5)

7

7

(100.0)

19

17

(89.5)

12

11

(91.7)

15

9

(60.0)

61

51

(83.6)

 If not active: No. of self-reported pharmacy visits, median (IQR)c

8

5

(3.5–5.5)

7

5

(4–7)

19

6

(4–9)

12

5.5

(3–11.5)

15

2

(1–4)

61

5

(3–7)

 Self-reported at least 6 pharmacy visitsd, n (%)

48

27

(56.3)

41

26

(63.4)

32

22

(68.8)

77

49

(63.6)

24

2

(8.3)

222

126

(56.8)

Change in BP

 Baseline SBP, mean (SD)

51

142.6

(15.9)

42

146.5

(16.7)

32

145.3

(10.3)

83

151.3

(15.1)

24

147.2

(13.9)

232

147.3

(15.2)

 Change in SBP, mean (SD)

51

−11.1*

(16.3)

42

−8.4*

(17.9)

32

−11.8*

(17.9)

83

−10.5*

(19.5)

24

−5.5

(17.3)

232

−9.9*

(18)

 Baseline DBP, mean (SD)

51

89.3

(11)

42

88.3

(12.8)

32

89.4

(9.5)

83

93.4

(11.1)

24

90

(10.6)

232

90.6

(11.2)

 Change in DBP, mean (SD)

51

−5.2*

(10.9)

42

−4.2*

(10.1)

32

−6.5*

(11.5)

83

−8.0*

(12)

24

−2.0

(11.5)

232

−5.9*

(11.4)

 BP on target at baseline, n (%)

51

15

(29.4)

42

16

(38.1)

32

5

(15.6)

83

18

(21.7)

24

2

(8.3)

232

56

(24.1)

 BP on target at endline, n (%)

51

29

(56.9)

42

25**

(59.5)

32

20

(62.5)

83

45

(54.2)

24

10

(41.7)

232

129**

(55.6)

 BP on target and/or improved at endline, n (%)

51

34

(66.7)

42

28

(66.7)

32

21

(65.6)

83

59

(71.1)

24

11

(45.8)

232

153

(65.9)

  1. a4 patients are excluded from this table, 2 patients with a BP < 140&90 at baseline who did not report use of antihypertensive medication and 2 patients who were referred from LUTH to the pilot program
  2. b4 patients did not know the number of visits they made to the pharmacy and are excluded (N = 161)
  3. c6 patients did not know the number of visits they made to the pharmacy and are excluded (N = 61)
  4. d10 patients did not know the number of visits they made to the pharmacy and are excluded (N = 222)
  5. *p < 0.05 in one-sample t-test on change between baseline and endline
  6. **p < 0.05 in Fisher’s exact-test on the difference between BP on target at baseline and endline
  7. SBP systolic blood pressure, DBP diastolic blood pressure, BP blood pressure
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us